2 FDA research centers see attrition in 2026 amid leadership turnover

In fiscal 2026, two key FDA research centers dealing with drug and biologics evaluation saw a net loss of 110 employees, with 354 leaving and 244 joining. This significant attrition comes amid leadership changes, potentially impacting the centers' ability to ensure the safety and efficacy of drugs in the U.S. Such shifts could lead to longer review times and affect public health, highlighting the critical need for stable leadership in regulatory bodies.